Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07311577) titled 'Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study' on Dec. 16, 2025.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Jiangsu Cancer Institute & Hospital
Condition:
Ovarian Cancer Metastatic
Ovarian Cancer Metastatic Recurrent
Intervention:
Drug: RC48+Carboplatin+Bevacizumab
Recruitment Status: Recruiting
Phase: Pha...